OTLK
Outlook Therapeutics (OTLK)
$55
About Outlook Therapeutics (OTLK)
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Details
Daily high
$0.58
Daily low
$0.55
Price at open
$0.58
52 Week High
$3.39
52 Week Low
$0.50
Market cap
36.8M
Dividend yield
0.00%
Volume
2.0M
Avg. volume
14.7M
P/E ratio
-.53
Outlook Therapeutics News
Details
Daily high
$0.58
Daily low
$0.55
Price at open
$0.58
52 Week High
$3.39
52 Week Low
$0.50
Market cap
36.8M
Dividend yield
0.00%
Volume
2.0M
Avg. volume
14.7M
P/E ratio
-.53